677 Lower risk of cardiovascular (CV) events and death in men receiving ADT by gonadotropin releasing hormone (GnRH) antagonist, degarelix, compared with luteinising hormone-releasing (LHRH) agonists
| Autor: | Tombal, B., Albertsen, P., De La Taille, A., Van Der Meulen, E., Persson, B-E., Olesen, T.K., Nilsson, J. |
|---|---|
| Zdroj: | In European Urology Supplements March 2013 12(1):e677-e678 |
| Databáze: | ScienceDirect |
| Externí odkaz: |
|
Full Text from ScienceDirect